NRC

$17.73

Market ClosedAs of Mar 17, 8:00 PM UTC

National Research Corporation provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$17.73
Potential Downside
20.3%
Whystock Fair Value$14.12
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryHealth Information Services

National Research Corporation provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for ...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$403.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
35.46
Beta
Defensive asset. Lower volatility than the S&P 500.
0.58
Div Yield
Strong income play. Yield provides a meaningful total return floor.
316.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
51.24%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.43

Recent News

Insider Monkey
Mar 13, 2026

What Makes National Research Corporation (NRC) a Good Investment Choice?

Long Cast Advisers, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, the Portfolio’s cumulative net return increased by 1%, but the cumulative portfolio for the year remained flat. Since its inception in November 2015, the portfolio has delivered a cumulative return […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 9, 2026

NRC's Q4 Earnings Down Y/Y on High Client Attrition, Stock Falls 27%

NRC Health's Q4 EPS and revenues decline year amid prior client attrition, though recurring contract value grew 8%, pointing to recovery prospects in 2026.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 4, 2026

A Look At The Fair Value Of National Research Corporation (NASDAQ:NRC)

Key Insights National Research's estimated fair value is US$15.13 based on 2 Stage Free Cash Flow to Equity Current...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 4, 2026

National Research Q4 Earnings Call Highlights

National Research (NASDAQ:NRC) executives pointed to improving sales momentum and recurring contract value growth during the company’s fourth-quarter earnings call, while acknowledging year-over-year revenue pressure tied to elevated attrition experienced in 2024. Fourth-quarter results For the fou

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Jan 30, 2026

National Research Says Pairing NPS With HCAHPS Can Boost Patient Experience—and Reimbursement

National Research (NASDAQ:NRC) leaders Sarah Fryda and Jason Messerli told webcast attendees that hospitals can use Net Promoter Score (NPS) and other real-time patient feedback tools to strengthen performance on the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey, a

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.